GSK-3915393 is under clinical development by GSK and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect GSK-3915393’s likelihood of approval (LoA) and phase transition for Celiac Disease took place on 29 Jul 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their GSK-3915393 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
GSK-3915393 is under development for the treatment of celiac disease. The drug candidate is administered orally. It is a small molecule that acts by targeting transglutaminase-2 (TG2).
GSK is a healthcare company that focuses on developing, manufacturing and commercializing pharmaceuticals, vaccines and consumer healthcare products. It offers drugs for the treatment of diseases such as HIV, respiratory, cancer, immuno-inflammation, anti-viral, central nervous system (CNS), metabolic, cardiovascular and urogenital, anti-bacterials, dermatology and rare diseases. The company also offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and gastro-intestinal diseases. GSK’s vaccine portfolio covers various diseases including hepatitis, diphtheria, tetanus, whooping cough, rotavirus and HPV infections, measles and bacterial meningitis, among others. The company sells its products through wholesalers, pharmacies, hospitals, physicians and other groups worldwide. GSK is headquartered in Brentford, Middlesex, the UK.
Quick View GSK-3915393 LOA Data
|Highest Development Stage|